Cullinan Therapeutics (CGEM) Projected to Post Quarterly Earnings on Thursday

Cullinan Therapeutics (NASDAQ:CGEM) is expected to post its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Cullinan Therapeutics to post earnings of ($0.80) per share and revenue of $3.6670 million for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, May 11, 2026 at 9:30 AM ET.

Cullinan Therapeutics (NASDAQ:CGEM) last announced its quarterly earnings data on Tuesday, March 10th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.03. On average, analysts expect Cullinan Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cullinan Therapeutics Stock Performance

Shares of CGEM traded down $0.99 during trading hours on Tuesday, hitting $14.36. The stock had a trading volume of 486,042 shares, compared to its average volume of 776,689. Cullinan Therapeutics has a 12-month low of $5.68 and a 12-month high of $16.74. The firm has a market cap of $882.11 million, a P/E ratio of -4.29 and a beta of -0.09. The company’s fifty day simple moving average is $14.22 and its 200 day simple moving average is $11.70.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Wall Street Zen lowered Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, February 8th. Wedbush increased their target price on shares of Cullinan Therapeutics from $34.00 to $36.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 11th. BTIG Research restated a “buy” rating and issued a $38.00 price target on shares of Cullinan Therapeutics in a report on Monday. HC Wainwright boosted their price objective on shares of Cullinan Therapeutics from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cullinan Therapeutics in a research report on Friday, April 10th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $29.89.

Insiders Place Their Bets

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 8,000 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $15.68, for a total value of $125,440.00. Following the completion of the transaction, the insider owned 170,844 shares in the company, valued at $2,678,833.92. This represents a 4.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jacquelyn L. Sumer sold 3,601 shares of Cullinan Therapeutics stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $14.47, for a total transaction of $52,106.47. Following the sale, the insider owned 128,089 shares in the company, valued at $1,853,447.83. This represents a 2.73% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 78,492 shares of company stock valued at $1,113,359. Company insiders own 6.07% of the company’s stock.

Institutional Investors Weigh In On Cullinan Therapeutics

A number of large investors have recently added to or reduced their stakes in CGEM. Caitong International Asset Management Co. Ltd lifted its holdings in Cullinan Therapeutics by 62.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,696 shares of the company’s stock worth $28,000 after buying an additional 1,036 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Cullinan Therapeutics by 44.6% during the second quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company’s stock worth $62,000 after acquiring an additional 2,523 shares during the last quarter. Quarry LP acquired a new position in shares of Cullinan Therapeutics in the fourth quarter worth about $99,000. Massar Capital Management LP purchased a new position in Cullinan Therapeutics in the second quarter valued at about $101,000. Finally, Great Lakes Advisors LLC acquired a new stake in Cullinan Therapeutics during the 4th quarter valued at approximately $128,000. 86.31% of the stock is owned by institutional investors and hedge funds.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.